AUTL
Autolus Therapeutics is an early commercial-stage biopharmaceutical company developing CAR T cell therapies for oncology and autoimmune diseases. The company's lead program AUCATZYL (obecabtagene autoleucel, or obe-cel), a CD19-targeted CAR T cell therapy, was FDA-approved in November 2024 for relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and launched commercially in January 2025, with additional approvals and launches in the United Kingdom and European Commission. Obe-cel is also advancing in clinical development for pediatric B-ALL and B-NHL in the Phase 2 CATULUS trial, severe refractory systemic lupus erythematosus in the Phase 1 CARLYSLE trial and Phase 2 LUMINA trial for lupus nephritis, and progressive multiple